Dr. Chris Martin, DPhil, MBA

Chairman and Non Executive Director MyricxBio Ltd at Myricx Bio

Speaker

Chris is a renowned biotech company founder, director and entrepreneur, and a pioneer and leader in the antibody-drug conjugate (ADC) space.

He was instrumental in co-founding ADC Therapeutics in 2012 and served as its CEO since inception until 2022. Under his leadership, ADC Therapeutics grew from a private biotech start-up to a New York Stock Exchange (NYSE) listed leader in the field of ADCs with products on the global market.

Earlier in his career he co-founded and was the CEO of Spirogen Ltd, an innovator of ADC payload technology, which was acquired by MedImmune, now a member of the AstraZeneca group. Prior to the acquisition, Chris led numerous Spirogen collaboration transactions, including agreements with Genentech and Seattle Genetics and post-acquisition he served for two years as VP Spirogen, AstraZeneca.

Alongside his role as Chairman of Myricx, he is also Chairman of the Board of Tokamak Energy Ltd, and Tagworks Pharmaceuticals BV, and a Director on the Boards of Osivax SAS and Senya Ltd.

Chris is a Fellow of the Institution of Chemical Engineers and a Sainsbury Management Fellow, he holds a bachelor’s degree in chemical engineering from Aston University, a DPhil in Engineering Science from the University of Oxford, and an MBA from IMD Business School.